Cormica Opens Medical Device Chemistry Lab in Bradford

Combination product manufacturers navigating dual regulatory pathways now have a consolidated analytical resource: Cormica has opened a dedicated Medical Device Chemistry laboratory at its Bradford Centre of Excellence, completing the integration of pharmaceutical and medical device analytical chemistry under one roof at Listerhills Science Park.

The consolidation is a direct response to the growing complexity of drug-device submissions, where QA and regulatory teams must satisfy both 21 CFR Part 211 pharmaceutical standards and medical device chemistry requirements simultaneously. Cormica's Bradford site brings more than 20 years of GMP pharmaceutical testing experience into direct alignment with its medical device chemistry capability, creating a single platform for regulatory-ready data generation across the full product lifecycle.

The operational logic behind the restructure is equally significant. By transferring medical device chemistry services from Cormica's Dover facility, Medical Engineering Technologies Ltd, the Dover site gains capacity to concentrate on physical, functional, transit, and packaging testing. The network-level effect is a cleaner delineation of centres of excellence, reducing the risk of capability overlap and allowing each site to deepen technical focus.

Dr Ben Cliff, Chief Transformation Officer at Cormica, framed the strategic intent plainly: combination devices require a joined-up understanding of pharmaceutical and medical device requirements, and manufacturers need testing partners able to bridge disciplines. Dr Caroline German, Operations Director at Cormica Bradford, noted that consolidating analytical chemistry services creates an environment where pharmaceutical rigour and medical device insight operate side by side, supporting development of next-generation combination products.

For QA directors and regulatory affairs leads managing combination product submissions, the practical implication is access to integrated analytical support, advanced separation sciences, and specialist physical characterisation within a single GMP-aligned site. The Bradford laboratory's instrumentation and quality systems are positioned to support data packages from early development through to product release, reducing the coordination burden that typically arises when pharmaceutical and device testing are handled by separate providers.

The Bradford opening marks a measurable step in Cormica's broader network investment, with the Dover site's expanded specialist focus representing the next operational checkpoint to watch.

Source: Cormica Pharma & Med Device Testing via cormica.com, 7 September 2026.